About Henan Taloph Pharmaceutical Stock Company

The company was founded in 1993 and listed on the Shanghai Stock Exchange in 1999. It is the first listed company in the pharmaceutical industry in Henan Province. In the future, the company will continue to focus on the company's development strategy, focus on the main business, and consolidate the foundation. While maintaining the steady growth of the traditional Chinese medicine business and the continuous improvement of R&D service capabilities throughout the CXO industry chain, the company will further promote the high-quality development of the company in combination with technological innovation and industrial fund investment collaboration. The company's main business is pharmaceutical manufacturing and drug research and development services, which specifically include the four business segments of pharmaceutical preparations, Chinese medicine tablets, drug research and development services, and pharmaceutical herbal medicine distribution. The main products include Shuanghuanglian oral liquid series, Shuangjin combination, pediatric fever and cough relief oral liquid, pediatric antipyretic oral solution, agastache zhengqi combination, salvia oral solution, salvia drink, pediatric compound chicken neijin chewables, huxerine tablets, Wuzi Yanzong oral liquid, compound yimu oral liquid, etc. Among them, Shuangjin Conjugate, Shuanghuanglian Oral Liquid (children's type), Shuanghuanglian, and Pediatric Compound Chicken Neijin Chewables are the company's exclusive products/dosage forms. Corporate honors: “Main Enterprise in the Advanced Manufacturing Industry Chain in Zhengzhou”, the Pharmaceutical Industry Chamber of Commerce of the All-China Federation of Industry and Commerce awarded the company the honor of “Anti-epidemic, Charity and Love”, Henan High-tech Enterprise, “National High-tech Industrialization Demonstration Project”, “Excellent Enterprise in Zhengzhou”, selected as “2022 Top 100 Chinese Pharmaceutical Industry Enterprises” by the China Traditional Chinese Medicine Association, and “2022 Top 100 Proprietary Chinese Medicine Enterprises” by the Henan Provincial People's Government, and “Key Leading Enterprise of Henan Province for Agricultural Industrialization (2024)” and “Anti-epidemic Supply and Protection Responsibility” by the China Non-Prescription Drug Association “Responsible enterprises”, the “2022 Top 20 Science and Technology Innovation Enterprises” in the Zhengzhou High-tech Zone, the “Top Ten Municipal High-tech High-growth High-value-added Enterprises”, and the “2024 Advanced Science and Technology Innovation Units” in the Zhengzhou High-tech Zone.